Table 2.
Baseline characteristics of the 335 newly diagnosed NPC patients enrolled in the study
| Characteristic | Number of patients | % |
|---|---|---|
| Age at diagnosis | ||
| Range (years) | 17-79 | |
| Median age (years) | 50 | |
| Sex | ||
| Male | 240 | 71.6 |
| Female | 95 | 28.4 |
| T stage* | ||
| T1 | 13 | 3.9 |
| T2 | 101 | 30.1 |
| T3 | 143 | 42.7 |
| T4 | 78 | 23.3 |
| N stage* | ||
| N0 | 4 | 1.2 |
| N1 | 64 | 19.1 |
| N2 | 235 | 70.1 |
| N3 | 32 | 9.6 |
| Clinical stage* | ||
| II | 26 | 7.8 |
| III | 208 | 62.1 |
| IV | 101 | 30.1 |
| IC regimens | ||
| TPF | 54 | 16.1 |
| TP | 155 | 46.3 |
| GP | 71 | 21.2 |
| PF | 22 | 6.6 |
| No | 33 | 9.8 |
| Treatment modality | ||
| IC+CRT+AC | 165 | 49.3 |
| IC+IMRT+AC | 14 | 4.2 |
| IC+CRT | 115 | 34.3 |
| IC+IMRT | 8 | 2.4 |
| CRT | 13 | 3.9 |
| CRT+AC | 20 | 5.9 |
IC: induction chemotherapy; CRT: concurrent chemoradiotherapy; AC: adjuvant chemotherapy; IMRT: intensity-modulated radiotherapy; TPF: docetaxel/cisplatin/fluorouracil; TP: docetaxel/cisplatin; GP: gemcitabine/fluorouracil; FP: cisplatin/fluorouracil.
*American Joint Committee on Cancer/International Union against Cancer staging system, seventh edition.